Supplements to Take Advantage of the Most Anabolic Hormone Insulin

Chromium Picolinate increases muscle cell insulin sensitivity.

Alpha Lipoid Acid (ALA) is an anti-oxidant that increases insulin sensitivity and glucose metabolism.

Cinnamon delays gastric emptying, lowesr blood glucose levels following meals and reduces fasting insulin.

Berberine is an sensitizer that increases the use of the anabolic hormone insulin.

Cyanidin 3-glucoside (C3G) effects insulin signaling, selective insulin sensitivity, glucose and nutrient repartitioning.

Apple Cider Vinegar (ACV) lowers glucose and insulin responses and increases satiety after a bread meal in health.

Ursolic Acid shows promise as a repartitioning agent.

Vanadyl Sulfate helps with uptake of glucose into muscle cells instead of fat cells. 

Natural Ways to Reduce Estrogen Dominance

 

#helpYOUgetGAINS 
Twitter: @helpYOUgetGAINS

DIM

In healthy young men, it cuts "bad" estrogens in half by helping the liver neutralize them. DIM doesn't actually reduce estrogens. What is does is help the liver convert them into weaker forms.

Take 200-300 mg as 2-3 divided doses.

Calcium-D-Glucarate

Calcium D-glucarate attaches itself to estrogens in your intestines and passes them out into your toilet bowl. Otherwise, your body's could reabsorb a significant amout of estrogens that your body intends to eliminate. The only possible downside is that it also helps remove excess testosterone and cortisol, but only the overspill that's already destined for elimination. Take 800-600 mg as 2-8 divided doses.

Damiana Extract

University of Mississippi (Oxford) researchers discovered that damiana leaf extract inhibits the aromatase enzyme that converts testosterone into estrogen in the body. Take 50-500 milligrams three times per day between meals.

Chrysin

5, 7-dihydroxyflavone or chrysin is a flavonoid compound found in many plants and in honey. It has been known for years to inhibit the aromatase enzyme and block the conversion of testosterone into estrogen. Recent research from Texas Tech University (Lubbock) finds that it can also directly increase testosterone production. Take 1 gram of chrysin with breakfast, lunch and dinner.

Methoxyisoflavone

Is an anti-estrogen supplement. It lowers estrogen promoting higher testosterone levels. It also has been found to enhance protein synthesis and lower cortisol levels. Take 500-2,000mg per day in three divided doses with meals

Indole-3-carbinol (I3C)

A closely related derivative diindolylmethane (DIM), naturally occurring phytochemicals also reduces the strength of estrogens by converting them to weaker varieties in the liver.

The new entry's (most are natural ingredients that bind to estrogen receptors):

Resveratrol

Known as the ingredient from the French paradox, resveratrol is a SERM type product that has many other health promoting benefits. Resveratrol has been shown in studies to not only block estrogen but and increase LH leading to higher testosterone levels.

Ellagic Acid

This is typically an extract of raspberries and pomegranate. It has been studied to block estrogen.

Daidzein

This is the soy paradox. We typically say don't take soy. Daidzein which is a metabolite of soy that has weak estrogenic activity.

Grape Seed Extract.

Many studies have shown Grape Seed Extract to be a good aromatase inhibitor.

URSOLIC ACID
This poly phenol found in the skin of apples has been shown to increase muscle growth and strength by increasing production of IGF-1 and reducing the amount of testosterone that gets converted to estrogen. It has also been shown to increase fat loss while simultaneously building more muscle. Take 250-l,500mg 30-60 minutes before workouts.

Ipriflavone or 7-hydroxyflavone

Doses equivalent to about 500 mg for humans, easily reachable with lpriflavone supplements. Studies have found that serum testosterone levels increased, estrogen levels decreased, and muscle RNA went up 5%-10% (meaning more muscle protein was being directed) due to aromatase inhibition.

Stinging nettle

Ori Hofmekler (The Warrior Diet) lists this as having anti-aromatase agent. I will have to do further research.

Safflower Seed

Carthamus tinctorius (Compositae) as an anti-estrogenic. Studies have shown that tracheloside significantly decreased the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme. As such CLA has also been pro ported to have anti-estrogenic capabilities.

VITEX AGNUS CASTUS

Chaste tree or Vitex agnus castus contains the active compounds known as agnosides that work to reduce estrogen levels and boost luteinizing hormone (LH) levels. In males, this can lead to a dramatic increase in testosterone. Take 200-400 mg of vitex agnus castus or chasteberry extract immediately before bed. Take it in 6-8-week cycles, then lay off for about four weeks before starting the next cycle.

Citrus Bioflavonoids

Hesperetin is created by metabolising hesperidin in the stomach which is found in citrus fruits, especially orange. Naringenin is another citrus bioflavonoid whose metabolites are able to lower aromatase enzyme and estrogen. They do this by attaching to receptor sites.

Bee Propolis

Has been shown to be effective in the fight against xenoestrogens.

Vitamin D

Has been shown to be a natural aromatase inhibitor.

Turmeric

Has promise as an aromatase inhibitor by occupying estrogen receptors. 

 Aggressive Strength Testosterone Booster -Estrogen Control Combo

Sources:

Damiana + chrysin: stack these two aminos to send nitric oxide levels skyrocketing.  Jim Stoppani.

Flex. 27.9 (Nov. 2009): p132.

"Grow your chest, not your breasts." Men's Fitness July 2002: 66+.

Your T, on E. Murphy, Myatt. Men's Health, Sep2012, Vol. 27 Issue 7, p86-87, 2p

ERADICATE ESTROGEN TO FUEL YOUR GROWTH. Rowley, Brian. Stoppani, Jim. Joe Weider's Muscle & Fitness, Oct2003, Vol. 64 Issue 10, p176

ESTROGEN NATION. Lockwood, Chris. Joe Weider's Muscle & Fitness, Nov2009, Vol. 70 Issue 11, p94-97


 References:

Araujo, A., Chiu, G., Kupelian, V., Rosen, R., & McKinlay, J. (2010, May 29). Relative contributions of modifiable risk factors to erectile dysfunction [Abstract 17]. Journal of Urology, 183(Suppl. 4), e7-e8.

Araujo, A., Durante, R., Feldman, H. A., Goldstein, I., & McKinlay, J. B. (1998). The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosomatic Medicine, 60, 458-465.

Azadzoi, K. M., & Saenz de Tejada, I. (1991). Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. Journal of Urology, 146, 238-240.

Bacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003). Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Annals of Internal Medicine, 139, 161-168.

Buvat, J., Montorsi, F., Maggi, M., Porst, H., Kaipia, A., Colson, M. H., et al. (2011). Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST Study). Journal of Sexual Medicine, 8, 284-293.

Caminiti, G., Volterrani, M., & Iellamo, F. (2009). Effect of longacting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. Journal of the American College of Cardiology, 54, 919-927.

Cheng, J. Y., & Ng, E. M. (2007). Body mass index, physical activity and erectile dysfunction: A U-shaped relationship from a populationbased study. International Journal of Obesity, 31, 1571-1578.

Corona, G., Mannucci, E., Lotti, F., Boddi, V., Jannini, E. A., Fisher, A. D., et al. (2009). Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. Journal of Sexual Medicine, 6, 2591-600.

Corona, G., Mannucci, E., Schulman, C., Petrone, L., Mansani, R., Cilotti, A., et al. (2006). Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. European Urology, 50, 595-604.

Corona, G., Monami, M., Boddi, V., Balzi, D., Melani, C., Federico, N., et al. (2010). Is obesity a further cardiovascular risk factor in patients with erectile dysfunction? Journal of Sexual Medicine, 7, 2538-2546.

Daubenmier, J. J., Weidner, G., Marlin, R., Crutchfield, L., Dunn-Emke, S., Chi, C., et al. (2006). Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology, 67, 125-130.

Davidson, J. M., Chen, J. J., Crapo, L., Gray, G. D., Greenleaf, W. J., & Catania, J. A. (1983). Hormonal changes and sexual function in aging men. Journal of Clinical Endocrinology and Metabolism, 57, 71-77.

De Boer, B. J., Bots, M. L., Lycklama a Nijeholt, A. A., Moors, J. P., Pieters, H. M., & Verheij, T. J. (2004). Erectile dysfunction in primary care: Prevalence and patient characteristics. The ENIGMA study. International Journal of lmpotence Research, 16, 358-364.

Derogatis, L. R., & Burnett, A. L. (2008). The epidemiology of sexual dysfunctions. Journal of Sexual Medicine, 5, 289-300.

Dod, H. S., Bhardwaj, R., Sajja, V., Weidner, G., Hobbs, G. R., Konat, G. W., et al. (2010). Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. American Journal of Cardiology, 105, 362-367.

Duncan, B. B., & Schmidt, M. I. (2001). Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Medical Journal, 119, 122-127.

Dunn-Emke, S., Weidner, G., Pettengill, E., Marlin, R. O., Chi, C., & Ornish, D. (2005). Nutritional adequacy of a very low-fat vegan diet. Journal of the American Dietetic Association, 105, 1442-1446.

Esposito, K., Giugliano, F., DiPalo, C., Giugliano, G., Marfella, R., D'Andrea, F., et al. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. Journal of the American Medical Association, 291, 2978-2984.

Esposito, K., Giugliano, F., Maiorino, M. I., & Giugliano, D. (2010). Dietary factors, Mediterranean diet and erectile dysfunction. Journal of Sexual Medicine, 7, 2338-2345.

Everitt, B. J. (1995). Neuroendocrine mechanisms underlying appetitive and consummatory elements of masculine sexual behaviour. In J. Bancroft (Ed.), The pharmacology of sexual function and dysfunction (pp. 15-31). Amsterdam, the Netherlands: Excerpta Medica.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001).

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.

Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J.,& McKinlay, J. B. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology, 151, 54-61.

Feldman, H. A., Johannes, C. B., Derby, C. A., Kleinman, K. P., Mohr, B. A., Araujo, A. B., et al. (2000). Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Preventive Medicine, 30, 328-338.

Giltay, E. J., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J., Saad, F., & Kalinchenko, S. Y. (2010). Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine, 7, 2572-2582.

Gluckman, P. D., & Hanson, M. A. (2004). The developmental origins of the metabolic syndrome. Trends in Endocrinology and Metabolism, 15, 183-187.

Gooren, L. J. G. (1987). Androgen levels and sex functions in testosterone-treated hypogonadal men. Archives of Sexual Behavior, 16, 463-473.

Gray, A., Feldman, H. A., McKinlay, J. B., & Longcope, C. (1991). Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism, 73, 1016-1025.

Hannan, J. L., Maio, M. T., Komolova, M., & Adams, M. A. (2009). Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. Journal of Sexual Medicine, 6(Suppl. 3), 254-261.

Heinemann, L. A., Zimmermann, T., Vermeulen, A., & Thiel, C. (1999). A new "Aging Male's Symptoms" (AMS) Rating Scale. Aging Male, 2, 105-114.

Isidori, A. M., Caprio, M., Strollo, F., Moretti, C., Frajese, G., Isidori, A., et al. (1999). Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism, 84, 3673-3680.

Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E. J., Moncada, I., et al. (2010). Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome: The TIMES2 Study. Diabetes Care. Manuscript submitted for publication.

Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J., Giltay, E. J., & Saad, F. (2010). Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clinical Endocrinology, 73, 602-612.

Kalyani, R. R., & Dobs, A. S. (2007). Androgen deficiency, diabetes, and the metabolic syndrome in men. Current Opinion in Endocrinology, Diabetes and Obesity, 14, 226-234.

Kaukua, J., Pekkarinen, T., Sane, T., & Mustajoki, P. (2003). Sex hormones and sexual function in obese men losing weight. Obesity Research, 11, 689-694.

Khaw, K. T., Dowsett, M., & Folkerd, E. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 116, 2694-2701.

Kim, J. H., Klyachkin, M. L., Svendsen, E., Davies, M. G., Hagen, P. O., & Carson, C. C., III. (1994). Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. Journal of Urology, 151, 198-205.

Koncz, L., & Balodimos, M. C. (1970). Impotence in diabetes mellitus. Medical Times', 98, 159-170.

Kratzik, C. W., Lackner, J. E., Mark, I., Rticklinger, E., Schmidbauer, J., Lunglmayr, G., et al. (2009). How much physical activity is needed to maintain erectile function? Results of the Androx Vienna Municipality Study. European Urology, 55, 509-516.

Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., & Salonen, R. (2003). Sex hormones, inflammation, and the metabolic syndrome: A population-based study. European Journal of Endocrinology, 149, 601-608.

Larsen, S. H., Wagner, G., & Heitmann, B. L. (2007). Sexual function and obesity. International Journal of Obesity, 31, 1189-1198.

Leenen, R., van der Kooy, K., Seidell, J. C., Deurenberg, P.,& Koppeschaar, H. P. (1994). Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. Journal of Clinical Endocrinology and Metabolism, 78, 1515-1520.

Legros, J. J., Meuleman, E. J., Elbers, J. M., Geurts, T. B., Kaspers, M. J., & Bouloux, P. M. (2009). Oral testosterone replacement in symptomatic late-onset hypogonadism: Effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology, 160, 821-831.

Lehman, T. P., & Jacobs, J. A. (1983). Etiology of diabetic impotence. Journal of Urology, 129, 291-294.

Lewis, R. W., Fugl-Meyer, K. S., Corona, G., Hayes, R. D., Laumann, E. O., Moreira, E. D. Jr., et al. (2010). Definitions/epidemiology/ risk factors for sexual dysfunction. Journal of Sexual Medicine, 7, 1598-1607.

Lindau, S. T., & Gavrilova, N. (2010). Sex, health, and years of sexually active life gained due to good health: Evidence from two US population-based cross sectional surveys of ageing. British Medical Journal, 340, c810.

Maggio, M., Lauretani, F., Ceda, G. P., Bandinelli, S., Ling, S. M., Metter, J., et al. (2007). Relationship between low levels of anabolic hormones and 6-year mortality in older men: The aging in the Chianti Area (InCHIANTI) study. Archives of Internal Medicine, 167, 2249-2254.

McNamara, E. R., Alfred-Thomas, J. A., & Freedland, S. J. (2010, June 1). Exercise correlates to higher sexual function scores in a cohort of healthy men [Abstract 1500]. Journal of Urology, 183(Suppl. 4), e578.

Meinhardt, W., Kropman, R. F., Vermeij, P., Nijeholt, A. A. B.,& Zwartendijk, J. (1997). The influence of medication on erectile function. International Journal of Impotence Research, 9, 17-26.

Meuleman, E. J., Donkers, L. H., Robertson, C., Keech, M., Boyle, P., & Kiemeney, L. A. (2001). Erectile dysfunction: Prevalence and effect on the quality of life; Boxmeer study. Nederlands Tijdschrift voor Geneeskunde, 145, 576-581.

Meuleman, E. J., & van Lankveld, J. J. (2005). Hypoactive sexual desire disorder: An underestimated condition in men. British Journal of Urology International, 95, 291-296.

Mooradian, A. D., Morley, J. E., & Korenman, S. G. (1987). Biological actions of androgens. Endocrine Reviews, 8, 1-28.

Nelson, R. J. (2000). An introduction to behavioral endocrinology (2nd ed.). Sunderland, MA: Sinauer.

Nieschlag, E. (1979). The endocrine function of the human testis in regard to sexuality. In Ciba Foundation Symposium 62--Sex, hormones and behaviour (pp. 182-208). Amsterdam, the Netherlands: Excerpta Medica.

Okabe, H., Hale, T. M., Kumon, H., Heaton, J. P., & Adams, M. A. (1999). The penis is not protected--In hypertension there are vascular changes in the penis which are similar to those in other vascular beds. International Journal of Impotence Research, 11, 133-140.

Ornish, D., Brown, S. E., Scherwitz, L. W., Billings, J. H., Armstrong, W. T., Ports, T. A., et al. (1990). Can lifestyle changes reverse coronary heart disease?: The Lifestyle Heart Trial. Lancet, 336, 129-133.

Park, M. G., Oh, M. M., Lee, D. S., Yu, J. W., & Bae, J. H. (2010, June 1). The characteristics and predictive factors of nonresponders to testosterone replacement therapy in testosterone deficiency syndrome [Abstract 1381]. Journal of Urology, 183(Suppl. 4), e533-e534.

Prins, J., Blanker, M. H., Bohnen, A. M., Thomas, S., & Bosch, J. L. (2002). Prevalence of erectile dysfunction: a systematic review of population-based studies. International Journal of Impotence Research, 14, 422-432.

Rask, E., Olsson, T., Soderberg, S., Andrew, R., Livingstone, D. E., Johnson, O., et al. (2001). Tissue-specific dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism, 86, 1418-1421.

Reaven, G. M. (1988). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.

Rizvi, S. J., Kennedy, S. H., Ravindran, L. N., Giacobbe, P., Eisfeld, B. S., Mancini, D., et al. (2010). The relationship between testosterone and sexual function in depressed and healthy men. Journal of Sexual Medicine, 7, 816-825.

Rodriguez, A., Muller, D. C., Metter, E. J., Maggio, M., Harman, S. M., Blackman, M. R., et al. (2007). Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. Journal of Clinical Endocrinology and Metabolism, 92, 3568-3572.

Rosen, R. C., Friedman, M., & Kostis, J. B. (2005). Lifestyle management of erectile dysfunction: The role of cardiovascular and concomitant risk factors. American Journal of Cardiology, 96, 76M-79M.

Rosmond, R., Wallerius, S., Wanger, P., Martin, L., Holm, G.,& Bjorntorp, P. (2003). A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. Journal of Internal Medicine, 254, 386-390.

Saltzman, E. A., Guay, A. T., & Jacobson, J. (2004). Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observation. Journal of Urology, 172, 255-258.

Saylor, P. J., & Smith, M. R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology, 181, 1998-2008.

Schouten, B. W., Bohnen, A. M., Dohle, G. R., Groeneveld, F. P., Willemsen, S., Thomas, S., et al. (2009). Risk factors for deterioration of erectile function: The Krimpen study. International Journal of Andrology, 32, 166-175.

Schroeder, E. T., Zheng, L., Ong, M. D., Martinez, C., Flores, C., Stewart, Y. R., et al. (2004). Effects of androgen therapy on adipose tissue and metabolism in older men. Journal of Clinical Endocrinology and Metabolism, 89, 4863-4872.

Seidell, J. C., Bjorntorp, P., Sjostrom, L., Kvist, H., & Sannerstedt, R. (1990). Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels but negatively with testosterone levels. Metabolism, 39, 897-901.

Shabsigh, R., Kaufman, J. M., Steidle, C., & Padma-Nathan, H. (2004). Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology, 172, 658-663.

Shiri, R., Koskimaki, J., Hakkinen, J., Auvinen, A., Tammela, T. L., & Hakama, M. (2007). Cardiovascular drug use and the incidence of erectile dysfunction. International Journal of Impotence Research, 9, 208-212.

Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006). Low serum testosterone and mortality in male veterans. Archives of Internal Medicine, 166, 1660-1665.

Simons, L. P. A., & Hampe, J. F. (2010, June). Service experience design for healthy living support: Comparing an in-house with an eHealth solution. Paper presented at the 23rd Bled eConference eTrust on Implications for the Individual, Enterprises and Society, Bled, Slovenia.

Speel, T. G., Kiemeney, L. A., Thien, T., Smits, P., & Meuleman, E. J. (2005). Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: A pilot study. Journal of Sexual Medicine, 2, 207-212.

Stull, V. B., Snyder, D. C., & Demark-Wahnefried, W. (2007). Lifestyle interventions in cancer survivors: Designing programs that meet the needs of this vulnerable and growing population. Journal of Nutrition, 137(Suppl. 1), 243S-248S.

Stulnig, T. M., & Waldhausl, W. (2004). 11beta-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia, 47, 1-11.

Traish, A. M. (2009). Androgens play a pivotal role in maintaining penile tissue architecture and erection: A review. Journal of Andrology, 30, 363-369.

Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology, 30, 10-22.

Traish, A. M., Saad, F., Feeley, R. J., & Guay, A. (2009). The dark side of testosterone deficiency: III. Cardiovascular disease. Journal of Andrology, 30, 477-494.

Walker, B. R. (2001). Steroid metabolism in metabolic syndrome X. Best Practice & Research in Clinical Endocrinology and Metabolism, 15, 111-122.

Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H., Hellstrom, W. J., Gooren, L. J., et al. (2009). ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male, 12, 5-12.

White, J. R., Case, D. A., McWhirter, D., & Mattison, A. M. (1990). Enhanced sexual behavior in exercising men. Archives of Sexual Behavior, 19, 193-209.

Wild, S. H., & Byrne, C. D. (2006). The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In C. D. Byrne & S. H. Wild (Eds.), The metabolic syndrome (pp. 1-33). Weinheim, Germany: Wiley.

You, D., Ji, Y. I., Moon, K., Hong, J. H., & Ahn, T. H.0 (2010, May 31). The association of the metabolic syndrome and its components with the serum testosterone level: Results of a large volume screened population cohort [Abstract 707]. Journal of Urology, 183(Suppl. 4), e276.

Zitzmann, M., Faber, S., & Nieschlag, E. (2006). Association of specific symptoms and metabolic risks with serum testosterone in older men. Journal of Clinical Endocrinology and Metabolism, 91, 4335-4343.

Aggressive Strength Natural Testosterone Booster 

We are what we repeatedly do. Excellence, then, is not an act, but a habit. -- Aristole

— KCKCCTEC (@KCKCCTEC) April 28, 2016

 You have power over your mind - not outside events. Realize this, and you will find strength ~ Marcus Aurelius

Ursobolic is an amazing body recompostioning agent that contains the active ingredient Ursolic acid.

What is Ursobolic?

Ursobolic is an amazing body recompostioning agent that contains the active ingredient Ursolic acid. Ursolic acid is a chemical compound found in many plants and it belongs to class of compounds called pentacyclic triterpene acids.

In June of 2011 a landmark paper was published in the prestigious journal Cellular Metabolism, and the research was performed by scientists from the University of Iowa. In this paper they exploited techniques that involved gene technology to identify ursolic acid as a potent muscle builder and fat burner. Ursolic acid was shown to block the muscle wasting caused by starvation and denervation (severing of the nerves to a muscle). Ursolic acid was also shown to accelerate muscle growth by as much as 15% when fed to normal mice. Interestingly, fat loss occurred simultaneously and at a rate practically inversely proportional to muscle gain. It was almost as if fat was turning into muscle!

This potent ingredient has the potential to transform your physique even without a change in diet. The researchers found that one of its main mechanisms is through enhancing the expression of muscular IGF-1 gene. The local production of IGF-1 in muscle is perhaps the single most instrumental process in the muscle hypertrophy response as it initiates the key steps of satellite cell recruitment into new myonuclei and protein synthesis via the kinase Akt.

Ursolic acid shrinks fat cells. It is believed that it achieves this by both enhancing lipolysis (fat burning) and blocking fatty acid synthesis. It my also affect fat stores by blocking the cortisol activating enzyme 11b-HSD1. With Ursobolic, the increased energy demands of simultaneous growing muscles will be fed by the body fat stores.

Interestingly, Ursolic acid has also been shown to be an effective blocker of the enzyme aromatase, so it has the potential to control estrogen production and maximize testosterone release.
E-Pharm Ursobolic Benefits

* Anti-Catabolic
* Muscle Builder
* Fat Burner
* Non-Hormonal
* Estrogen Control
* Safe and Natural

What can I expect from Ursobolic?

First of all, Ursolic acid is not a bulking product. Yes it builds muscle but it does not put massive amounts of weight on you. This is because muscle growth will be accompanied by fat loss. The scale may not change much but the mirror will reflect what is going on – a dramatic change in body composition. You may experience a little bit of appetite suppression with Ursobolic as your body will be utilizing fat stores more efficiently for energy production. Ursobolic is fat soluble so for maximum absorption it should be taken with meals that contain a little bit of fat. The product is non-hormonal and safe, so it does not have to be cycled.

Nutrition Facts † Serving Size 3 Capsules Servings Per Container 40
Amount Per Serving
	Serving	% DV
Ursolic Acid	150 mg	-
Proprietary Blends
Ursolic Acid (from Rosemary) (600mg total extract)
*percent Daily Values are based on a 2,000 calorie diet.
Ingredients: Gelatin, Microcrystalline Cellulose, Modified Corn Starch, Silica, Magnesium Stearate.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. †Nutrition Facts are a simulation of the product's "Nutrition Label". For the actual Nutrition Label please refer to the product packaging.

Directions

Consume 3-6 capsules three times a day with food. This product does not have to be cycled.

Warnings

This product is only intended to be consumed by healthy adults 18 years of age or older. Before using this product consult with your physician if you are using any prescription or over the counter medicine, if you are unaware of your current medical condition or if you have any pre-existing medical condition. Discontinue use and consult your health care professional if you experience any adverse reaction to this product. Do not exceed recommended serving. Store in a cool, dry place with lid tightly closed. Do not use if inner safety seal is broken or missing. Keep out of reach of children.

When Patrick Arnold talks performance enhancement, you should listen.

Who is Patrick Arnold from his blog:

Patrick Arnold is an organic chemist who is renowned in the field of performance enhancement and sports supplements.  Patrick first hit the public eye in the late 1990’s when he introduced androstenedione (“andro”) to the market place.   Andro became widely known after it was linked to Mark Maguire in 1998 – the year he broke the seasonal home run record.  Patrick later went on to develop several other “prohormone” supplements such as 4-AD and 1-AD.  1-AD was considered by many to be the most effective and most popular prohormone ever developed.

Patrick is unique in the supplement industry because not only does he discover and introduce novel ingredients, but he uses his skills in organic synthesis to develop manufacturing processes for these ingredients.  Together with his business partner Lakhan Boodram, he actually carries out the commercial production of many of these ingredients and maintains his own strict quality oversight.
Despite all these accomplishments, Patrick may be best known as the man who developed the designer steroids that were behind the Balco scandal.  The most widely known of these steroids was tetrahydrogestrinone, also known as THG or “The Clear”.  Patrick was convicted for his role in the Balco scandal and served prison time.

In addition to Patrick’s work with prohormones and steroids he also is credited with introducing many successful ingredients to the supplement market place such as ipriflavone, 1,3-dimethylamylamine (i.e. Geranamine®), and phenibut.

Patrick currently produces products for the nutritional supplement company E-pharm Nutrition, as well as for Prototype Nutrition.  He continues to be perhaps the number one driving force in the advancement of performance enhancing nutritional supplementation.

Patrick Arnold's Prototype Nutrition.

 

Pump Spray Information from the E-Pharm website:

Pump Spray - Arginine Ursolic Acid
Arginine ursolic acid is an enhanced version of a natural compound known as ursolic acid. You may have never heard of ursolic acid before, but take my word for it when I tell you that it has more potential to change the way your body looks and functions than any chemical compound available outside of drugs and hormones. In fact, it has the potential to actuallyoutperform many of these drugs and hormones. The key word here is potential. For ursolic acid to really work – to unlock its potential – one needs to do a little chemical magic to it. But before I explain all that in detail, let’s first briefly look at what ursolic acid is.

Ursolic Acid
Ursolic acid is found in many plants, fruits, and vegetables and it belongs to class of compounds called pentacyclic triterpene acids.

Ursolic acid has been studied for decades. Scientists have known for quite some time that it has a wide variety of health benefits ranging from antioxidant potential and cancer prevention to protection against diabetes. Scientists have also made intriguing findings regarding ursolic acid’s effects on fat metabolism and storage that seem to suggest the compound may be a dieter’s dream. But it wasn’t until a couple of years ago that research came out that really caught everyone’s eye. Since then, two landmark papers have been published by a research team from a major American university and these papers have made ursolic acid front page headlines.

The papers showed that ursolic acid given to mice caused them to lose fat and gain muscle – not just a little bit, but a lot. Their muscles produced much more of a growth factor known as IGF-1, and the levels of protein synthesis and storage were increased. The ursolic acid mice could even eat more than other mice and they would still burn a lot more fat. This was due to their greater amounts of calorie burning muscle tissue as well as increased levels of a unique kind of metabolically active fat called brown fat. Brown fat is full of an enzyme called UCP-1, and this enzyme burns calories and releases heat in a process known as thermogenesis (you may notice an increased body temperature after using Pump Spray due to this thermogenesis as well as due to peripheral vasodilation effects).
A very interesting aspect of ursolic acid is something that was hinted at in older researched and then confirmed by this latest research. It has to do with increased production of endothelial nitric oxide. This is the nitric oxide that is produced in the blood vessels and causes them to expand and increase blood flow. The research scientists also discovered that ursolic acid activated a substance called vascular endothelial growth factor-A. This substance actually stimulates the production of new blood vessels. New blood vessels are needed to support the metabolic needs of growing tissue such as muscle. It is these effects on blood vessel physiology that are at the heart of the “pump” inducing and vascular enhancement properties of Pump Spray.

How we made Ursolic Acid work
Straight up ursolic acid is strange stuff. It dissolves very poorly in most fatty like solvents and it completely repels water (if you stick it in water it actually floats and stays completely dry). These properties make it extremely poorly absorbed. You see, for things to get absorbed they have to have some sort of solubility in either oil or water, and since ursolic acid is so poor in both regards the lion’s share of material just doesn’t get where it needs to go. This applies for both orally and topically applied ursolic acid.

So the challenge is to improve ursolic acid’s solubility characteristics such that it is able to be absorbed efficiently. We used what is known as the “pro-drug” approach (in our case, the term “pro-nutrient” would be more applicable). With this approach one alters the structure of the compound with hydrolysable functional groups in such a way that its chemical properties are improved. A hydrolysable group is something like an ester, certain ethers, amides etc. that your body will be able to efficiently convert back into the parent compound once it has been absorbed.

We took advantage of the chemistry of ursolic acid to add an acetate ester (forming ursolic acetate, which is itself actually a known natural derivative of ursolic acid). However, esterification was not enough since although ursolic acid’s lipid solubility was greatly improved, it still suffered from poor aqueous solubility. So we developed a method to link up the acid group of ursolic acid with the highly basic amino acid arginine. Acids react with bases to form salts, and salts are have superior solublity in water compared to their parent acids.

The resulting compound – arginine ursolic acid – has remarkable solubility characteristics. It dissolves fantastically in most organic solvents and disperses like soap in water. Consequently, it absorbs and penetrates very effectively.

When applied to the skin it absorbs rapidly and efficiently. The end effect is the initiation of subcutaneous fat dissolution and vasodilation effects that over time lead to dramatic changes in muscular definition and fullness. The benefits of ursolic acid can thusly be achieved in a manner that is impossible to match by any other means currently available.

Arginine ursolic acetate is but one half of the magic of Pump Spray. The other half is triacetyladenosine. Together these ingredients in our special topical base will give you unbelievable fat burning, muscle pumping, and vascularizing effects that you never thought possible from a natural supplement.

*Arginine ursolic acetate and other amino acid and amino acid derivative salts of ursolic acid esters are covered under a pending patent.

Pump Spray - Triacetyladenosine
Adenosine is an important molecule that serves a wide variety of roles in the function of cells throughout the body. You may be familiar of it as a component of adenosine triphosphate (ATP), which is the energy transfer molecule that keeps our body and brains working. You may also have heard of cyclic AMP, which is a cellular messenger that carries the signal for such things as adrenaline to fat and muscle. Less well known though is the fact that adenosine itself is a very important signaling molecule, especially in regards to blood flow. In particular (and of most interest to us) is the effect of adenosine on blood flow to muscles.


When muscles are exercised, ATP starts to become depleted. This cascade of depletion leads first to adenosine diphosphate (ADP), then to adenosine monophosphate (AMP), and finally to free adenosine. This free adenosine formed is then released from the muscle during contraction under conditions of low pH (as lactic acid accumulates). Outside the muscle it then interacts with adenosine receptors on the surface of the muscle cell, the neuromuscular junction, as well as the capillaries that feed the muscle. Adenosine serves to open up the capillaries to help the working muscle stay supplied with nutrients and oxygen, as well as to take away metabolic waste products. Additionally, adenosine’s interactions with its receptors on the muscle cell initiates what is known as the exercise mediated stimulation of glucose uptake. The muscle cells thereby take in and process glucose rapidly directly – without the presence of insulin being required.

The effect of adenosine on muscular blood flow is well recorded and is dramatic. Infusions of adenosine have been shown to increase blood flow and glucose uptake in skeletal muscle several fold. This happens very rapidly. Adenosine however must be infused into the blood stream since it is such a rapidly metabolized compound. In fact, its half-life is less than ten seconds. This is due primarily to the action of an enzyme called adenosine deaminase. This enzyme irreversibly converts adenosine to a compound known as inosine.


The unstable nature of adenosine is unfortunate, as it makes its administration for physique and exercise enhancement problematic. Some have tried to overcome this by offering it in the form of ATP, however this does not really solve the problem because once it is converted to adenosine (and this happens rapidly during digestion) it once again becomes susceptible to adenosine deaminase and much of it is destroyed. Very little of it reaches the muscles.

We can protect adenosine from this rapid and destructive deamination reaction. By making one of the hydroxyl groups (5’) on the ribose portion of the molecule into an ester, it has been found that the action of adenosine deaminase is blocked. The protection of this hydroxyl group allows the compound extended lifetime in the body, so that it may reach target tissues. Esterases at target tissues then regenerate the parent adenosine, where it may then interact with the appropriate adenosine receptors and impart its valuable pharmacological properties.

Epharm has chosen to use the acetate ester for protection of adenosine. For purposes of convenience all three hydroxyl groups are made into acetates, and the end product is called triacetyladenosine. Utilization of the ester form has an additional benefit, as it renders the compound soluble in organic solvent bases. This allows it to be suitable for use in a topical formula, and that is exactly what we decided to do with Pump Spray.


By optimizing the influence of adenosine on the skeletal muscle you can achieve maximum capillary vasodilation. This is manifested in what is known as exercise induced hyperemia, or more commonly referred to as “the pump”. Adenosine does more than just allow for vasodilation in the muscle however, it also is known to mediate the exercise induced secretion of vascular endothelial growth factor (VEGF). This growth factor serves the purpose to promote the formation of new capillaries, thereby augmenting the vascular network that feeds muscles for contraction as well as new growth.
Below are just a sample of references to just a few of the many articles published on the role of adenosine in muscle and exercise induced hyperemia. It is clearly apparent that adenosine plays a key role in the physical response to exercise, and with the introduction of triacetyladenosine as a component of Pump Spray you are finally able to capitalize fully on its potential!!

Acta Physiol Scand. 2001 Feb;171(2):177-85.
Role of adenosine in exercise-induced human skeletal muscle vasodilatation.
Rådegran G, Calbet JA.
Acta Biochim Pol. 2006;53(2):269-78. Epub 2006 Jun 12.
Adenosine as a metabolic regulator of tissue function: production of adenosine by cytoplasmic 5'-nucleotidases.
Borowiec A, Lechward K, Tkacz-Stachowska K, Składanowski AC.
Hypertension. 2009 Jun;53(6):993-9. Epub 2009 May 11.
Adenosine contributes to blood flow regulation in the exercising human leg by increasingprostaglandin and nitric oxide formation.
Mortensen SP, Nyberg M, Thaning P, Saltin B, Hellsten Y.

J Appl Physiol. 2006 Aug;101(2):492-9. Epub 2006 Apr 13.
Bimodal distribution of vasodilator responsiveness to adenosine due to difference in nitric oxidecontribution: implications for exercise hyperemia.
Martin EA, Nicholson WT, Eisenach JH, Charkoudian N, Joyner MJ.

J Appl Physiol. 2010 Feb;108(2):378-86. Epub 2009 Nov 25.
Comparison of exogenous adenosine and voluntary exercise on human skeletal muscle perfusionand perfusion heterogeneity.
Heinonen I, Kemppainen J, Kaskinoro K, Peltonen JE, Borra R, Lindroos MM, Oikonen V, Nuutila P, Knuuti J, Hellsten Y, Boushel R, Kalliokoski KK.
Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H857-62. Epub 2010 Jun 11.
Contraction-induced secretion of VEGF from skeletal muscle cells is mediated by adenosine.
Høier B, Olsen K, Nyberg M, Bangsbo J, Hellsten Y.
Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R385-90. Epub 2011 Nov 30.
Effects of adenosine, exercise, and moderate acute hypoxia on energy substrate utilization of human skeletal muscle.
Heinonen I, Kemppainen J, Kaskinoro K, Peltonen JE, Sipilä HT, Nuutila P, Knuuti J, Boushel R, Kalliokoski KK.
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R283-R296.
Growth regulation of the vascular system: an emerging role for adenosine.
Adair TH.
Hypertension. 2010 Dec;56(6):1102-8. Epub 2010 Nov 1.
Interstitial and plasma adenosine stimulate nitric oxide and prostacyclin formation in humanskeletal muscle.
Nyberg M, Mortensen SP, Thaning P, Saltin B, Hellsten Y.
J Physiol. 2001 Nov 1;536(Pt 3):927-35.
Oxygen delivery and oxygen consumption in rat hindlimb during systemic hypoxia: role ofadenosine.
Edmunds NJ, Marshall JM.
J Appl Physiol. 2007 Dec;103(6):2042-8. Epub 2007 Sep 20.
Role of adenosine in regulating the heterogeneity of skeletal muscle blood flow during exercise inhumans.
Heinonen I, Nesterov SV, Kemppainen J, Nuutila P, Knuuti J, Laitio R, Kjaer M, Boushel R, Kalliokoski KK.
Adv Exp Med Biol. 1998;441:97-106.
Role of adenosine in regulation of carbohydrate metabolism in contracting muscle.
Hespel P, Richter EA.
J Physiol. 2007 Sep 15;583(Pt 3):835-45. Epub 2007 Jul 5.
The roles of adenosine and related substances in exercise hyperaemia.
Marshall JM.
Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H857-62. Epub 2010 Jun 11.
Contraction-induced secretion of VEGF from skeletal muscle cells is mediated by adenosine.
Høier B, Olsen K, Nyberg M, Bangsbo J, Hellsten Y.

Pump Spray - Neovascularization
Neovascularization (also known as angiogenesis) is the formation of new vascular pathways. In the case of skeletal muscle, neovascularization is a healthy response that is stimulated by exercise. Intense exercise stimulates reactions in the muscle which increase its size, strength, as well as endurance. To support this larger and stronger muscle tissue there must be a corresponding increase in the ability of your body to feed the new tissue. This is where neovascularization comes into play.
Many people hit plateaus in training. Their muscles grow only so big and then they find it hard to make any further gains. This can be due to limitations in many areas, including the ability to activate genes that promote protein synthesis and/or an inability to repress genes responsible for protein degradation. It may also of course be due to inadequate intake of proper protein, calories, and essential nutrients to support muscle growth. Another possibility is that the body is unable to supply the muscle with the proper oxygen and substrates needed to support growth because the network of blood vessels and capillaries feeding it have not been adequately developed.

Much like how an army can only advance so far without adequate supply lines, your muscles can only grow so large without adequate vascular infiltration. This is where Pump Spray comes to the rescue. Pump Spray's two ingredients are proven to increase the production of vascular endothelial growth factor -1 (VEGF1), which is the signal protein released by muscle when it undergoes stress due to exercise that depletes oxygen and energy substrates. VEGF1 signals the muscles to sprout new blood vessels and capillaries off of existing ones to facilitate the growth and metabolic adaptations needed to handle the exercise strain.

By supporting and enhancing your body's own natural neovascularization response, you ensure that you maintain optimal anabolic supply lines so that your muscles can continue their hypertrophic blitzkrieg offensive! Not to mention the fact that roadmap veins covering your muscles definitely make a formidable fitness statement!

For further technical reading regarding the ingredients in Pump Spray and their roles in neovascularization of muscle tissue check out the following references.

Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H857-62. Epub 2010 Jun 11.
Contraction-inducesecretion of VEGF from skeletal muscle cells is mediated by adenosine.
Høier B,  Olsen K,  Nyberg M,  Bangsbo J,  Hellsten Y.
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R283-R296.
Growth regulation of the vascular system: an emerging role for adenosine.
Adair TH.
High Alt Med Biol. 2008 Summer;9(2):158-66.
Skeletal muscle capillarity during hypoxia: VEGF and its activation.
Breen E,  Tang K,  Olfert M,  ;Knapp A,  Wagner P.
J Appl Physiol. 1999 May;86(5):1513-8.
Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression.
Benoit H, Jordan M, Wagner H, Wagner PD.
Adv Exp Med Biol. 2001;502:349-63.
Roles of adenosine and nitric oxide in skeletal muscle in acute and chronic hypoxia.
Marshall JM.
Biochem Biophys Res Commun. 2008 Jul 4;371(3):556-60. Epub 2008 Apr 28.
Modulation of angiogenic factors by ursolic acid.
Kiran MS,  Viji RI,  Sameer Kumar VB,  Sudhakaran PR.
 J Agric Food Chem. 2010 Dec 22;58(24):12941-9. Epub 2010 Nov 12.
Ursolic acid induces allograft inflammatory factor-1 expression via a nitric oxide-related mechanism and increasesneovascularization.
Lee AW,  Chen TL,  Shih CM,  Huang CY,  Tsao NW,  Chang NC,  Chen YH,  Fong TH,  Lin FY.
Can J Cardiol. 1986 Mar-Apr;2(2):120-3.
Angiogenesis in the heart and skeletal muscle.Hudlicka O,  Wright AJ,  Ziada AM